Literature DB >> 9590295

Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.

J A Rafael1, J M Tinsley, A C Potter, A E Deconinck, K E Davies.   

Abstract

Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease usually resulting in death of patients by their early twenties. In contrast, mice lacking dystrophin (Dmd(mdx)), appear physically normal despite their underlying muscle pathology. Mice deficient for both dystrophin and the dystrophin-related protein, utrophin, (Dmd(mdx);Utrn-/- mice) die between 6 and 20 weeks of age suffering from severe muscle weakness with joint contractures, pronounced growth retardation and kyphosis, suggesting that dystrophin and utrophin play complementary roles. The exact cause of death in these mice was not determined. Here we show that expression of a truncated utrophin transgene solely within the skeletal muscle of these mutants prevents premature death and the development of any clinical phenotype. In the absence of full-length dystrophin and utrophin, the presence of truncated utrophin also decreases muscle fibre regeneration, relocalizes the dystrophin protein complex to the sarcolemma and re-establishes a normal expression pattern of developmental muscle proteins. These data suggest that Dmd(mdx);Utrn-/- mice succumb to a skeletal muscle defect and that their reduced lifespan is not due to cardiac or neurogenic components. The phenotypic rescue observed demonstrates that the Dmd(mdx);Utrn-/- mice are an ideal model for testing gene delivery protocols for the expression of utrophin or dystrophin in skeletal muscle. To determine the cause of death of the Dmd(mdx):Utrn-/- mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590295     DOI: 10.1038/ng0598-79

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  83 in total

Review 1.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

2.  Sparing of the extraocular muscles in mdx mice with absent or reduced utrophin expression: A life span analysis.

Authors:  Abby A McDonald; Sadie L Hebert; Linda K McLoon
Journal:  Neuromuscul Disord       Date:  2015-09-06       Impact factor: 4.296

3.  The GTPase RhoA increases utrophin expression and stability, as well as its localization at the plasma membrane.

Authors:  Armelle Bonet-Kerrache; Mathieu Fortier; Franck Comunale; Cécile Gauthier-Rouvière
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

Review 4.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

5.  Alpha7beta1 integrin does not alleviate disease in a mouse model of limb girdle muscular dystrophy type 2F.

Authors:  Derek J Milner; Stephen J Kaufman
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

6.  Alterations of dystrophin-associated glycoproteins in the heart lacking dystrophin or dystrophin and utrophin.

Authors:  Katharine M Sharpe; Monica D Premsukh; DeWayne Townsend
Journal:  J Muscle Res Cell Motil       Date:  2013-10-06       Impact factor: 2.698

7.  Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice.

Authors:  Guy L Odom; Paul Gregorevic; James M Allen; Eric Finn; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

8.  B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Authors:  Paul J Thomas; Rui Xu; Paul T Martin
Journal:  Am J Pathol       Date:  2016-09       Impact factor: 4.307

9.  The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.

Authors:  Jung Hae Yoon; Kumaran Chandrasekharan; Rui Xu; Matthew Glass; Neha Singhal; Paul T Martin
Journal:  Mol Cell Neurosci       Date:  2009-05-12       Impact factor: 4.314

10.  Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

Authors:  Christine Péladeau; Aatika Ahmed; Adel Amirouche; Tara E Crawford Parks; Lucas M Bronicki; Vladimir Ljubicic; Jean-Marc Renaud; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2015-10-22       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.